USE AND PERSISTENCE OF GUSELKUMAB IN TREATMENT FOR RHEUMATIC AND DERMATOLOGICAL DISEASE



P. ORTIZ FERNANDEZ1, A. HERREROS FERNANDEZ2, P. FERNANDEZ-VILLACAÑAS FERNANDEZ2, P. SELVI SABATER², M. ALMANCHEL RIVADENEYRA2, R. AÑEZ CASTAÑO², M. ONTENIENTE CANDELA², E. URBIETA SANZ² 4CPS-176


🖞 1 REINA SOFÍA HOSPITAL, PHARMACY, MURCIA, SPAIN. 2 HOSPITAL GENERAL REINA SOFIA, PHARMACY, MURCIA, SPAIN.

Background and importance

Guselkumab is anti-interleukin-23 monoclonal antibody used in patients refractorys to other biological agents in clinical practice, for:

- Moderate to severe psoriasis (msPs)
- Psoriatic arthritis (PsA)

Aim and objectives




To analyse the profile of use and persistence of guselkumab in patients diagnosed with msPs and PsA

Material and methods

Observational, descriptive and retrospective study.
All patients who initiated treatment with guselkumab.
Data of sex, age, diagnostic, comorbidities, previous biological, start date, last dispensation date and the reasons for treatment discontinuation were collected from the medical records and prescription medications program.



The cumulative probability of treatment persistence was analysed by Kaplan-Meier and log-rank test to compare the survival along diagnostic, line of treatment and comorbidities using SPSS Statistics.



The **cumulative probability of guselkumab persistence** was 74.8% at 1 year and 67.3% at 2 years. Median persistence of guselkumab was 31.2months (95%CI: 21.2-41.2). Statistical differences in guselkumab's persistence in msPs vs PsA (14-36.7 months, p=0.059), however patients with or without prior anti-IL-17 therapy, with or without comorbidities, or according to the number of prior biologics did not show any statistical

differences.

Conclusion and relevance

Drug survival of guselkumab in this study is aceptable but main limitation is short follow-up time in some of the patients due to their recent coverage by the Spanish health system in PsA.